Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

McMaster University

$72,250.00

Microfluidic high-throughput screening device for C. elegans movement based assays

FY 2013-14

Summary
C. elegans is one of the most widely studied organisms that is of great importance in the study of molecularmechanisms underlying numerous biological and disease processes. Because C. elegans carries more than halfof human disease genes and utilizes many of the same mechanisms, the findings in this model can besuccessfully translated to humans. Furthermore, due to its small size (~1 mm, ~1,000 somatic cells), shortgeneration time (~2.5 days), and transparent body, C. elegans (worms) serves as an ideal laboratory model forunderstanding the role of human genes in diseases as well as an effective screen to determine the effect of drugcandidates in mitigating these diseases.However, current methods of screening worms involve observation of their movement and imaging themfollowing exposure to chemicals. These methods are qualitative, labor-intensive prone to human errors, timeconsuming, costly and not amenable to high throughput. Automation, standardization and parallelization ofscreening processes for model organisms is crucial in lowering their cost and enabling their widespread use indrug discovery. We propose to take a novel approach to develop microfluidic devices to study the response ofworms to various chemicals. This is based on our recent promising discovery that C. elegans respond toelectrical signals and move in a directed manner inside microfluidic channels. This discovery has allowed us,for the first time, to induce movement behaviour on demand and quantitatively measure its response. Here wepropose to combine electric stimuli based movement response of the worms with microfabrication andmicrofluidic technology to develop devices that will screen for drug candidates for Parkinson's disease in ahigh throughput manner. The successful outcome of this project will be a low cost device that can be used bybiologist and pharmaceutical researchers for drug candidate screening using animal models for Parkinson'sdisease. The technology developed can also be applied with suitable modifications for any movement baseddisorders, neurological diseases and even obesity and hypertension if expressed in C.elegans.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
399261-2011
Name nom
Selvaganapathy, Ponnambalam
Department département
Mechanical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
72250
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
515
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Instrumentation technology
Area of application fr
Technologie de l'instrumentation
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
3
Nb partie
3
Application title
Microfluidic high-throughput screening device for C. elegans movement based assays
Keyword
NSERC
Application summary
C. elegans is one of the most widely studied organisms that is of great importance in the study of molecularmechanisms underlying numerous biological and disease processes. Because C. elegans carries more than halfof human disease genes and utilizes many of the same mechanisms, the findings in this model can besuccessfully translated to humans. Furthermore, due to its small size (~1 mm, ~1,000 somatic cells), shortgeneration time (~2.5 days), and transparent body, C. elegans (worms) serves as an ideal laboratory model forunderstanding the role of human genes in diseases as well as an effective screen to determine the effect of drugcandidates in mitigating these diseases.However, current methods of screening worms involve observation of their movement and imaging themfollowing exposure to chemicals. These methods are qualitative, labor-intensive prone to human errors, timeconsuming, costly and not amenable to high throughput. Automation, standardization and parallelization ofscreening processes for model organisms is crucial in lowering their cost and enabling their widespread use indrug discovery. We propose to take a novel approach to develop microfluidic devices to study the response ofworms to various chemicals. This is based on our recent promising discovery that C. elegans respond toelectrical signals and move in a directed manner inside microfluidic channels. This discovery has allowed us,for the first time, to induce movement behaviour on demand and quantitatively measure its response. Here wepropose to combine electric stimuli based movement response of the worms with microfabrication andmicrofluidic technology to develop devices that will screen for drug candidates for Parkinson's disease in ahigh throughput manner. The successful outcome of this project will be a low cost device that can be used bybiologist and pharmaceutical researchers for drug candidate screening using animal models for Parkinson'sdisease. The technology developed can also be applied with suitable modifications for any movement baseddisorders, neurological diseases and even obesity and hypertension if expressed in C.elegans.